



1<sup>st</sup> April 2025

Glaxo Group Limited  
79 New Oxford Street  
London  
WC1A 1DG

T +44 (0)20 8047 5000

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the F.Y. ended March 31, 2025.**

In compliance with the provisions of regulation 31(4) of the SEBI (Substantial Acquisition of & Takeovers) Regulations, 2011 ('SAST Regulations'). We, Glaxo Group Limited, UK, for ourselves and on behalf of the promoter group of the GlaxoSmithKline Pharmaceuticals Limited ('the Company') hereby confirm and declare that we, the Promoters along with PAC (Persons Acting in Concert), have not made any encumbrance, directly or indirectly, during the financial year ended March 31, 2025 on the shares held by us in the Company. We further confirm that as on March 31, 2025, there are no shares of the company that are encumbered or pledged by us.

For **Glaxo Group Limited, UK**

A handwritten signature in cursive script that reads 'Claire MacLeod'.

Claire MacLeod, Authorised Signatory, Representing Corporate Director  
**Signature of the Authorised Signatory**

**(For on behalf of Promoters)**

- Glaxo Group Limited
- GlaxoSmithKline Pte Ltd
- Burroughs Wellcome International Limited
- ESKAYLAB LIMITED

Place: London

Date: 1<sup>st</sup> April 2025